Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-06-10
2008-12-02
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S267200
Reexamination Certificate
active
07459474
ABSTRACT:
Novel non-steroidal compounds are provided which are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders, and have the structurewhere A, B, and R1-R6are defined herein.
REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4046889 (1977-09-01), Ondetti et al.
patent: 4168267 (1979-09-01), Petrillo, Jr.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4316906 (1982-02-01), Ondetti et al.
patent: 4337201 (1982-06-01), Petrillo, Jr.
patent: 4344949 (1982-08-01), Hoefle et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4374829 (1983-02-01), Harris et al.
patent: 4379785 (1983-04-01), Weyer et al.
patent: 4432971 (1984-02-01), Karanewsky et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4452790 (1984-06-01), Karanewsky et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4572912 (1986-02-01), Yoshioka et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4639436 (1987-01-01), Junge et al.
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4722810 (1988-02-01), Delaney et al.
patent: 4749688 (1988-06-01), Haslanger et al.
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4904769 (1990-02-01), Rauenbusch
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5100889 (1992-03-01), Misra et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5223516 (1993-06-01), Delaney et al.
patent: 5225401 (1993-07-01), Seymour
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5346701 (1994-09-01), Heiber et al.
patent: 5354772 (1994-10-01), Kathawala
patent: 5362727 (1994-11-01), Robl
patent: 5366973 (1994-11-01), Flynn et al.
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5504080 (1996-04-01), Karanewsky
patent: 5506219 (1996-04-01), Robl
patent: 5525723 (1996-06-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5552397 (1996-09-01), Karanewsky et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5614492 (1997-03-01), Habener
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5712279 (1998-01-01), Biller et al.
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5760246 (1998-06-01), Biller et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5827875 (1998-10-01), Dickson, Jr. et al.
patent: 5885983 (1999-03-01), Biller et al.
patent: 5962440 (1999-10-01), Sulsky
patent: 6395767 (2002-05-01), Robl et al.
patent: 6414126 (2002-07-01), Ellsworth et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 0 060 668 (1982-09-01), None
patent: 0061798 (1982-10-01), None
patent: 0 079 022 (1983-05-01), None
patent: 0 080 822 (1983-06-01), None
patent: 0 221 025 (1987-05-01), None
patent: 0 142 146 (1988-08-01), None
patent: 0 481 522 (1992-04-01), None
patent: 0 534 363 (1993-03-01), None
patent: 0 629 627 (1994-12-01), None
patent: 0 534 396 (1996-10-01), None
patent: 0 534 492 (1996-12-01), None
patent: 0 595 610 (1997-05-01), None
patent: 0 599 444 (1998-01-01), None
patent: 0 818 448 (2003-11-01), None
patent: 2 596 393 (1987-10-01), None
patent: 2 103 614 (1983-02-01), None
patent: 2 205 837 (1988-12-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 86/07054 (1986-12-01), None
patent: WO 96/38144 (1996-12-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 97/12615 (1997-04-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/38722 (2000-07-01), None
patent: WO 02/076959 (2002-10-01), None
US 4,385,051, 05/1983, Oka et al. (withdrawn)
Firestein and Manning. “Signal transduction and transcription factors in rheumatic disease,” Arthritis and Rheumatism 1999, vol. 42, No. 4, pp. 609-621.
Abdel-Megid et al., J. Heterocyclic Chem, 39, pp. 105-108 (2002.
Liu et al., Institute Elemento-Organic Chem., Naikai Univ., vol. 19(2), pp. 232-236 (1998).
Johnson et al., J. Am. Chem. Soc., 124, pp. 11689-11698 (2002.
Shimizu et al., Synthetic Communications, 19 (11 & 12) pp. 2219-2227 (1989).
Ashworth, D.M. et al., “2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinial Chemistry Letters, vol. 6, No. 10, pp. 1163-1166 (1996).
Ashworth, D.M. et al., “4-Cyanothiazolidides as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinial Chemistry Letters, vol. 6, No. 22, pp. 2745-2748 (1996).
Attwood, M.R. et al., “New potent inhibitors of angiotensin converting enzyme”, FEBS, vol. 165, No. 2, pp. 201-206 (1984).
Baldwin, Jr., A.S., “The transcription factor NF-κB and human disease”, The Journal of Clinical Investigation, vol. 107, No. 1, pp. 3-6 (2001).
Bamberger, C.M. et al., “Glucocorticoid Receptor β, a Potential Endogenous Inhibitor of Glucocorticoid Action in Humans”, The Journal of Clinical Investigation, vol. 95, pp. 2435-2441 (1995).
Baum, T. et al., “Antihypertensive Activity of SCH 31846, a Non-Sulfhydryl Angiotensin-Converting Enzyme Inhibitor”, Journal of Cardiovascular Pharmacology, vol. 5, No. 4, pp. 655-667 (1983).
Biller, S.A. et al., “Isoprenoid (Phosphinylmethyl)phosphonates as Inhibitors of Squalene Synthetase”, Journal of Medicinal Chemistry, vol. 31, No. 10, pp. 1869-1871 (1988).
Biller, S.A. et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, No. 1, pp. 1-40 (1996).
Brandon, D.D. et al., “Genetic variation of the glucocorticoid receptor from a steroid-resistant primate”, Journal of Molecular Endocrinology, vol. 7, pp. 89-96 (1991).
Bundgaard, H., Chapter 5: “Design and Application of Prodrugs”, A Textbook of Drug Design and Development, Harwood Academic Publishers, publ., Krogsgaard-Larsen, P. et al., eds., pp. 113-191 (1991).
Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., publ. (1985) (table of contents).
Bundgaard, H., “Prodrugs as a means to improve the delivery of peptide drugs”, Advanced Drug Delivery Reviews, vol. 8, pp. 1-38 (1992).
Caldenhoven, E. et al., “Negative Cross-Talk between ReIA and the Glucocorticoid Receptor: A Possible Mechanism for the Antiinflammatory Action of Glucocorticoids”, Molecular Endocrinology, vol. 9, No. 4, pp. 401-412 (1995).
Capson, T.L., “Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis”, dissertation, Department of Medicinal Chemistry, University of Utah, pp. iv-v, Table of Contents, 16-17, 40-43, 48-51, Summary (June 1987).
Chakravarti, D. et al., “Role of CBP/P300 in nuclear receptor signalling”, Nature, vol. 383, pp. 99-103 (1996).
Cohen, D.M. et al., “CI-925: A New Orally Active Non-sulfhydryl Angiotensin Converting Enzyme (ACE) Inhibitor” (53, 266), The Pharmacologist, FASEB Meeting Information, vol. 26, No. 1, p. 177 (1984).
Corey, E.J. et al., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demonstration That ‘Presqualene Pyrophosphate’ Is an Essential Intermediate on
Moree Wilna J.
Robinson Leslie A.
Rueter Jaimie K.
Bristol--Myers Squibb Company
Duncan Laurelee A.
Lewis Amy A
Marschel Ardin
LandOfFree
Modulators of the glucocorticoid receptor and method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of the glucocorticoid receptor and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of the glucocorticoid receptor and method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4038229